newsfilter
← Latest News
GlobeNewswire·

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

  • Retension Pharmaceuticals priced its upsized initial public offering of 3,750,000 common stock shares at $12.00 per share.
  • The offering is expected to generate gross proceeds of $45.0 million before deducting underwriting discounts & commissions.
  • Shares are expected to begin trading on the Nasdaq Capital Market under the ticker "RTSN" on October 9, 2026.
  • The offering is scheduled to close on or about October 13, 2026, subject to customary closing conditions.
  • Underwriters have a 30-day option to purchase up to an additional 562,500 shares at the initial public offering price.
  • Net proceeds will be used to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension & prepare for the planned Phase 3 trial.
  • Leerink Partners, Guggenheim Securities & Oppenheimer & Co. are acting as joint bookrunning managers.
  • Titan Partners is serving as the lead manager for the offering.
  • Registration statements became effective on October 8, 2026.
  • RTN-001 is a next-generation PDE5 inhibitor developed under an exclusive worldwide license from Sanofi S.A.